23:18 , Jan 18, 2019 |  BioCentury  |  Finance

Broken window

A combination of bad calendar luck and the U.S. government shutdown is trending toward this being one of the slowest Januarys for biotech public financings in recent years. But a few deals are getting done...
18:55 , Jan 17, 2019 |  BC Week In Review  |  Financial News

Alnylam raises $387.5M

Just over five months after gaining its first-ever approval of an RNAi therapy, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) has raised $387.5 million on Jan. 15 in a follow-on funding intended to build its commercial capabilities. Alnylam...
22:54 , Jan 15, 2019 |  BC Week In Review  |  Clinical News

FDA reviewing Pfizer's TTR amyloid cardiomyopathy therapy

Pfizer Inc. (NYSE:PFE) said FDA accepted for review two NDAs for tafamidis to treat transthyretin (TTR) amyloid cardiomyopathy based on two forms of the compound. The NDA for the tafamidis meglumine form was granted Priority...
05:08 , Jan 15, 2019 |  BC Extra  |  Financial News

Amid Onpattro launch, Alnylam raises $387.5M

Just over five months after gaining its first-ever approval of an RNAi therapy, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) has raised $387.5 million in a follow-on funding intended to build its commercial capabilities. Alnylam priced 5 million...
20:28 , Jan 14, 2019 |  BC Extra  |  Company News

FDA reviewing Pfizer's TTR amyloid cardiomyopathy therapy

Pfizer Inc. (NYSE:PFE) said FDA accepted for review two NDAs for tafamidis to treat transthyretin (TTR) amyloid cardiomyopathy based on two forms of the compound. The NDA for the tafamidis meglumine form was granted Priority...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech companies...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month's gains and losing $291.2 billion in aggregate value. Median losses...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
18:33 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

As Vir enters the clinic, Scangos sees future of HBV in combos

Vir Biotechnology Inc. (San Francisco, Calif.) started a Phase I/II trial of HBV therapy VIR-2218, marking the biotech's first clinical program and a stepping stone towards CEO George Scangos' goal of HBV combinations. VIR-2218 is...
00:10 , Nov 27, 2018 |  BC Extra  |  Clinical News

As Vir enters the clinic, Scangos sees future of HBV in combos

Vir Biotechnology Inc. (San Francisco, Calif.) started a Phase I/II trial of HBV therapy VIR-2218, marking the biotech's first clinical program and a stepping stone towards CEO George Scangos' goal of HBV combinations. VIR-2218 is...